Savara Inc Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Savara Inc (SVRA) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $340.00 thousand as of 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2020-03-12
- 2019-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $340.00K.
- 2018-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $503.00K.
- 2017-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $376.00K.
- 2016-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $253.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2019-12-31 | $340.00K 10-K · filed 2020-03-12 |
| 2018-12-31 | $503.00K 10-K · filed 2019-03-13 |
| 2017-12-31 | $376.00K 10-K · filed 2018-03-14 |
| 2016-12-31 | $253.00K 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |